|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.71 USD | -0.09% |
|
+1.71% | +0.73% |
| Apr. 18 | Sector Update: Health Care Stocks Mixed Pre-Bell Thursday | MT |
| Apr. 18 | Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study | MT |
April 18 (Reuters) - Cerevel Therapeutics said on Thursday its Parkinson's disease drug met the main goal of a late-stage trial. (Reporting by Sriparna Roy in Bengaluru; Editing by Savio D'Souza)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 2,854 JPY | -0.52% | +5.31% | 2.16B | ||
| 42.71 USD | -0.09% | +1.71% | 7.76B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +0.73% | 7.76B | |
| -3.46% | 102B | |
| +1.41% | 96.09B | |
| +2.13% | 22.28B | |
| -15.84% | 21.4B | |
| -9.28% | 18.14B | |
| -39.98% | 17.02B | |
| -14.65% | 16.09B | |
| +4.39% | 13.83B | |
| +31.35% | 11.97B |
CEREVEL THERAPEUTICS HOLDINGS, INC. 
